Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z003883 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
HBP confirmed the patient involved did not experience any medical concerns or symptoms after the administration of the improperly stored VARIVAX; HBP calling with a report of a report of an adverse event regarding an improperly stored and administered dose of VARIVAX. HBP stated that the VARIVAX was exposed to multiple temperature excursions beginning in May 2025 and stated that a dose of the; This spontaneous report was received from a consumer or other non-health professional and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drugs reactions and allergies were not reported. On 06-Jun-2025, the patient was vaccinated with an improperly storage dose of varicella virus vaccine live (oka-merck) (VARIVAX) 0.5 mL (dose frequency reported as two dose series) administered as prophylaxis (Lot No. Z003883 has been verified to be a valid lot number for [varicella virus vaccine live (oka-merck], expiration date reported and upon internal validation established as 03-Feb-2027) (strength, dose number, route and anatomical location of administration and vaccination scheme frequency were not provided); that was reconstituted with sterile diluent (Lot No., expiration date and indication were not provided) (Product storage error). Additionally, it was stated that the previous mention vaccine was exposed to multiple temperature excursions beginning in (May 2025). The patient involved did not experience any medical concerns or symptoms after the administration of the improperly stored varicella virus vaccine live (oka-merck) (VARIVAX). No additional adverse event (No adverse event).